Immodulon Therapeutics Ltd

Immodulon Therapeutics Limited is a private, clinical-stage, immuno-oncology company dedicated to the development of novel, safe and effective treatments for cancer patients. Our lead drug candidate, the immunomodulator IMM-101, has shown promise in early clinical trials, demonstrating clear potential for its use in a range of cancers and to complement the four major pillars of cancer treatments – immunotherapy, chemotherapy, radio/ablation therapy and surgery – and increase their efficacy without compromising patient’s safety and quality of life.